Acne Vulgaris
Conditions
Keywords
comedone extraction, oral doxycycline, moderate acne vulgaris, HIF-1 alpha expression
Brief summary
The objective of the study was to evaluate the effectiveness of comedone extraction compared to oral antibiotics as the main therapy of moderate acne vulgaris (MAV); and to determine the expression of HIF-1 alpha by examining the immunohistochemistry and ELISA as a sign of hypoxia/anoxia in MAV lesion. This was a randomized, placebo-controlled clinical trial that was performed in 2015 at three different dermatology clinics in Indonesia, Cipto Mangunkusumo Hospital Jakarta, Gatot Soebroto Army Hospital Jakarta, and PT. Mattel Indonesia, Cikarang. One hundred and twenty eight subjects with moderate acne vulgaris were recruited and randomized to receive either oral doxycycline or comedone extraction for six weeks. Subjects who had acne lesion and the back area were offered skin lesion biopsy to evaluate immunohistochemistry and ELISA before administration of medication. The main outcome was total reduction of inflammatory and non inflammatory lesions, evaluated every two weeks.
Detailed description
Acne vulgaris (AV) is a polymorphic disease, characterized by inflammatory and noninflammatory lesions. Systemic antibiotics play a role as the first line therapy of moderate acne vulgaris treatment. Since bacterial resistance tends to increase, alternative therapy for moderate acne vulgaris is needed. This study aims to evaluate the effectiveness of comedone extraction compared to oral antibiotics as the main therapy of moderate acne vulgaris; and to etermine the expression of HIF-1 alpha by examining the immunohistochemistry and ELISA as a sign of hypoxia/anoxia in MAV lesion. This was a randomized, placebo-controlled clinical trial that was performed in 2015 at three different dermatology clinics in Indonesia, Cipto Mangunkusumo Hospital Jakarta, Gatot Soebroto Army Hospital Jakarta, and PT. Mattel Indonesia, Cikarang. One hundred and twenty eight subjects, aged between 15 and 50 years, with moderate acne vulgaris were recruited and randomized to receive either oral doxycycline (100 mg) or comedone extraction for six weeks. Subjects who had acne lesion and the back area were offered skin lesion biopsy to evaluate immunohistochemistry and ELISA before administration of medication. At each follow-up visit, subjects were asked to grade the overall response and questioned regarding adverse events. The objective or main outcome was total reduction of inflammatory and noninflammatory lesions.
Interventions
Doxycycline capsule 100 mg/day, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
PROCEDUREComedone extraction
Comedone extraction, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
Sponsors
Indonesia University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients with moderate acne vulgaris based on clinical manifestation of face (20-100 comedones, 15-50 inflammatory lesions, and/or 30-125 total lesions) * Age range of 15 to 50 years old
Exclusion criteria
* History of oral antibiotics consumption within 2 weeks preceding this study * Usage of topical retinoid in less than previous 2 weeks * History of systemic retinoid consumption within 3 months preceding this study * Pregnant of breastfeeding women * Consuming oral contraception during examination * Drug allergy or skin manifestation due to side effect of moderate acne vulgaris first line therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline Non-Inflammatory Lesions at 6 weeks | 6 weeks | Numeric data of total reduction (improvement) of non-inflammatory lesions (Baseline non-inflammatory lesion count) - (Week 6 non-inflammatory lesion count) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ x 100% Baseline non-inflammatory lesion count |
| Change from Baseline Non-Inflammatory Lesions at 4 weeks | 4 weeks | Numeric data of total reduction (improvement) of non-inflammatory lesions (Baseline non-inflammatory lesion count) - (Week 4 non-inflammatory lesion count) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ x 100% Baseline non-inflammatory lesion count |
| Change from Baseline Inflammatory Lesions at 2 weeks | 2 weeks | Numeric data of total reduction (improvement) of inflammatory lesions (Baseline inflammatory lesion count) - (Week 2 inflammatory lesion count) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ x 100% Baseline inflammatory lesion count |
| Change from Baseline Inflammatory Lesions at 4 weeks | 4 weeks | Numeric data of total reduction (improvement) of inflammatory lesions (Baseline inflammatory lesion count) - (Week 4 inflammatory lesion count) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ x 100% Baseline inflammatory lesion count |
| Change from Baseline Inflammatory Lesions at 6 weeks | 6 weeks | Numeric data of total reduction (improvement) of inflammatory lesions (Baseline inflammatory lesion count) - (Week 6 inflammatory lesion count) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ x 100% Baseline inflammatory lesion count |
| Change from Baseline Non-Inflammatory Lesions at 2 weeks | 2 weeks | Numeric data of total reduction (improvement) of non-inflammatory lesions (Baseline non-inflammatory lesion count) - (Week 2 non-inflammatory lesion count) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ x 100% Baseline non-inflammatory lesion count |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Side Effects at 6 weeks | 6 weeks | * Mild side effects if it did not need further management and research medication could be continued. * Moderate side effects if clinical manifestations were robust, itchy, pain, erythematous, yet did not need further management and temporary. * Severe side effects if it interfered daily activity, such as burn and pain sensastion, erythematous skin, edema, skin exfoliation, that needed further management. |
| Subjective Improvement at 2 weeks | 2 weeks | Improvement of clinical manifestation based on subjective complaints. Subjects were asked to grade overall response using rating scale (0-4), with higher score means a better outcome (0) no or minimal improvement 1. mild improvement 2. moderate improvement 3. robust improvement 4. very good improvement |
| Subjective Improvement at 4 weeks | 4 weeks | Improvement of clinical manifestation based on subjective complaints. Subjects were asked to grade overall response using rating scale (0-4), with higher score means a better outcome (0) no or minimal improvement 1. mild improvement 2. moderate improvement 3. robust improvement 4. very good improvement |
| Subjective Improvement at 6 weeks | 6 weeks | Improvement of clinical manifestation based on subjective complaints. Subjects were asked to grade overall response using rating scale (0-4), with higher score means a better outcome (0) no or minimal improvement 1. mild improvement 2. moderate improvement 3. robust improvement 4. very good improvement |
| Number of Participants with Side Effects at 2 weeks | 2 weeks | * Mild side effects if it did not need further management and research medication could be continued. * Moderate side effects if clinical manifestations were robust, itchy, pain, erythematous, yet did not need further management and temporary. * Severe side effects if it interfered daily activity, such as burn and pain sensastion, erythematous skin, edema, skin exfoliation, that needed further management. |
| Number of Participants with Side Effects at 4 weeks | 4 weeks | * Mild side effects if it did not need further management and research medication could be continued. * Moderate side effects if clinical manifestations were robust, itchy, pain, erythematous, yet did not need further management and temporary. * Severe side effects if it interfered daily activity, such as burn and pain sensastion, erythematous skin, edema, skin exfoliation, that needed further management. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Expression of Antibody HIF-1 Alpha with Immunohistochemistry Examination | Baseline | Analysis of HIF-1 Alpha expression on keratinocyte cell of pilosebaceous ducts (samples from skin lesion biopsy) was examined with immunohistochemistry using antibody HIF-1 alpha which was visualized with microscope and photographed to achieve qualitative data. |
| Expression of Antibody HIF-1 Alpha with ELISA Examination | Baseline | The measurement of HIF-1 Alpha protein concentration in the sebaceous follicle ducts was conducted through ELISA examination with Cusabio Human Hypoxia-inducible factor |
Outcome results
None listed